Headlines

Evaluating Ultragenyx Pharmaceutical: Insights From 7 Financial Analysts

Latest Ratings for RARE

Date Firm Action From To
Feb 2022 Morgan Stanley Maintains Overweight
Feb 2022 JP Morgan Upgrades Neutral Overweight
Feb 2022 Morgan Stanley Maintains Overweight

View More Analyst Ratings for RARE

View the Latest Analyst Ratings

read more

Leave a Reply

Your email address will not be published. Required fields are marked *